AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Aug 05, 2021

Lessons from COVID-19’s cutaneous manifestations

Dermatologic symptoms may be the first notable sign of acute COVID-19 for some patients.


Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD
Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD

We have been learning that — like many bacterial and viral infections — COVID-19 can affect the skin. Dermatologic symptoms may be the first notable sign of acute COVID-19 for some patients. For some patients, dermatologic manifestations are the visible sign of SARS-CoV-2 infection.

These symptoms were examined in depth in a new session on Thursday, "Cutaneous Manifestations of COVID-19” (U004).

“We see a wide variety of skin manifestations with COVID-19,” said Sergey Rekhtman, MD, FAAD, PharmD, MPH, assistant professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and co-director at Inpatient Dermatology Consultation Service, Northwell Health. “The majority of these tend to be fairly harmless, like pernio and COVID toes, with minimal consequences for patients. Sometimes, we see signs of acute vascular injury as evidenced by retiform purpura or multisystem inflammatory syndrome (MIS). Dermatologists can help make the diagnosis and help with prognostication. We have a key role in helping patients understand how their skin reacts to COVID and COVID vaccination.”

Dr. Rekhtman co-directed the session with Sheila Shaigany, MD, FAAD, who focused on dermatologic reactions to COVID-19 vaccination. She is assistant professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and co-director of the Northwell Health Inpatient Dermatology Consultative Service.

Skin rash is one of the primary diagnostic criteria of MIS, Dr. Rekhtman said. With more than 3,000 distinct cutaneous presentations included in the broad term “rash,” dermatologists can help the care team distinguish between lookalikes, such as deep tissue pressure injury and the variety of purpuric features seen in COVID-19, as well as identify morbilliform rashes, urticaria, and other cutaneous features seen in moderate-to-severe COVID-19.

“We were in a unique position because we saw so many COVID-19 cases in New York last March through June,” Dr. Rekhtman said. “We can help provide insight into this problem because we were able to systematically evaluate a large number of patients in a very short time period.”

New York area clinicians were similarly immersed in COVID-19 vaccine trials and initial vaccination programs targeting health care providers. Dr. Shaigany noted that all the COVID vaccines in current use can produce injection site reactions, typically pain and swelling, much like any other vaccine.

The mRNA vaccines produced by Pfizer and Moderna can also induce delayed reactions. The Moderna vaccine, in particular, can have uncommon large local reactions that appear seven to eight days after injection.

“We are fortunate to have learned about these reactions through pivotal studies, such as the AAD/ILD COVID-19 vaccine registry. These delayed local reactions present as large, edematous pink plaques,” Dr. Shaigany said. “Up to half of these reactions may span more than 10 centimeters wide. Although these reactions can last longer than the more familiar acute injection site reaction (sometimes up to one week), they typically resolve without any complications.”

The usual treatment for delayed injection site reactions may include topical steroids, antihistamines, and cool compresses, she said. Although these reactions are thought to possibly represent a delayed type hypersensitivity response, they are not a contraindication to a second vaccine dose. Up to half of patients with delayed large local reactions may have a similar reaction to the second vaccine dose, but the second reaction is seldom more severe than the first.

Urticaria and morbilliform rashes have also been reported following mRNA COVID vaccination. Patients who develop urticaria within four hours of vaccination may be experiencing a Type 1 hypersensitivity reaction, which could be a contraindication to a second dose, especially when severe symptoms indicative of anaphylaxis are present. However, Type I hypersensitivity reactions are rare, and patients who develop hives or a morbilliform rash more than four hours after vaccination are not thought to be having an allergic reaction. Patients who are uncomfortable can be managed with antihistamines and topical steroids, Dr. Shaigany said. “And as far as we can tell, there is not an increased risk for recurrence of these rashes with the second dose."

“Some of the rashes we saw with COVID infection are also occurring after COVID vaccination, such as urticaria, morbilliform rashes, erythema multiforme, pernio, and pityriasis rosea,” Dr. Shaigany said. “This strengthens the hypothesis that these are immune-mediated reactions rather than reactions to the virus itself. When these rashes appear after vaccination, I sometimes tell patients, it means the vaccine is working, that your immune system is doing its job.”

Interesting Stories
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
More in Summer Meeting 2021
Peter Lio, MD, FAAD
Summer Meeting 2021
The secrets of minimizing pain
Aug 11, 2021
Lawrence S. Chan, MD, FAAD
Summer Meeting 2021
Biomedical advancements impact dermatologic diagnosis and treatment
Aug 11, 2021
Todd Schlesinger, MD, FAAD
Summer Meeting 2021
Update on managing advanced skin cancer
Aug 11, 2021
Hensin Tsao, MD, PhD, FAAD
Summer Meeting 2021
HPV vax, psoriasis biologics, and caregiver quality of life highlight FiRST session
Aug 11, 2021
07e
Summer Meeting 2021
Summer Meeting packed a welcome punch
Aug 11, 2021
Mario E. Lacouture, MD, FAAD
Summer Meeting 2021
Oncodermatology takes the stage at Fox Lectureship
Aug 06, 2021
Julie Gerberding, MD, MPH
Summer Meeting 2021
COVID-19: A “predictable surprise”
Aug 06, 2021
Aimee Payne, MD, PhD, FAAD
Summer Meeting 2021
Frost Lectureship traces mPV treatment’s path from lab to clinical trial
Aug 06, 2021
2020 Gold Medal Presentation | Professor R. Rox Anderson, MD (left), Lancer Endowed Chair in Dermatology, Harvard Medical School and Director, Wellman Center for Photomedicine at Mass. General Hospital. 2021 Gold Medal Presentation | Dirk Michael Elston, MD, FAAD (right), Medical University of South Carolina.
Summer Meeting 2021
Two physicians honored with AAD Gold Medal awards
Aug 05, 2021
Alina G. Bridges, DO, FAAD
Summer Meeting 2021
New science, technology, and dedication improve dermatopathology
Aug 05, 2021
Sm21 F008 1526e
Summer Meeting 2021
How to have mindful, effective conversations with patients
Aug 05, 2021
Charlene Lam, MD, MPH, FAAD
Summer Meeting 2021
“Uninvite” disaster by planning
Aug 05, 2021
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.